The long-acting C5 inhibitor, ravulizumab, is efficacious and safe in pediatric patients with atypical hemolytic uremic syndrome previously treated with eculizumab

BACKGROUND: Atypical hemolytic uremic syndrome (aHUS) is a rare, complement-mediated disease associated with poor outcomes if untreated. Ravulizumab, a long-acting C5 inhibitor developed through minimal, targeted modifications to eculizumab was recently approved for the treatment of aHUS. Here, we r...

Descripción completa

Detalles Bibliográficos
Autores principales: Tanaka, Kazuki, Adams, Brigitte, Aris, Alvaro Madrid, Fujita, Naoya, Ogawa, Masayo, Ortiz, Stephan, Vallee, Marc, Greenbaum, Larry A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2020
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910247/
https://www.ncbi.nlm.nih.gov/pubmed/33048203
http://dx.doi.org/10.1007/s00467-020-04774-2

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7910247/
https://www.ncbi.nlm.nih.gov/pubmed/33048203
http://dx.doi.org/10.1007/s00467-020-04774-2

Ejemplares similares